logo-loader

ANGLE looks to change the game for cancer detection after FDA approval for Parsortix

Last updated: 07:33 22 Jan 2024 GMT, First published: 13:39 30 Apr 2021 BST

Snapshot

  • ANGLE's liquid biopsy given boost by peer-reviewed research
  • ANGLE PLC: Making solid commercial progress
  • ANGLE CEO says latest cancer results "may turn out to be groundbreaking"
parsortix

About the company

ANGLE PLC is a world-leading liquid biopsy company with sample-to-answer solutions.

The company's proven patent-protected circulating tumour cell (CTC) harvesting technology is known as the Parsortix® system.

Parsortix® is FDA-cleared for its intended use in metastatic breast cancer and is currently the first and only FDA-cleared medical device to harvest intact circulating cancer cells from the blood.

How it is doing

22 Jan 2024

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technology, has hailed the publication of a peer-reviewed paper that highlights the potential of the company's Parsortix system in precision oncology, a field that is revolutionising cancer therapy.

The device allows for the harvesting of intact circulating tumour cells (CTCs) from a simple blood sample, providing a critical tool for cancer research, drug development, and clinical oncology.

Appearing in the journal 'Current Issues in Molecular Biology', the research, with contributions from several leading cancer centres worldwide, demonstrates the system's wide utility across various cancer types.

It particularly emphasises the combined analysis of CTCs and ctDNA (cell-free DNA) in a single blood sample, leading to more comprehensive biomarker profiles.

20 Jan 2024

Andrew Newland and Ian Griffiths, CEO and CFO respectively of ANGLE PLC (AIM:AGL, OTCQX:ANPCY), provided a comprehensive overview of the company's liquid biopsy device, Parsortix, and its recent developments in a presentation targeting investors.

ANGLE, specialising in cancer diagnostics, developed Parsortix to separate cancer cells from blood, offering insights into cancer's progression and enabling repeat biopsies. Traditional tissue biopsies become outdated as cancer evolves, but Parsortix allows for ongoing monitoring of changes in cancer cells.

04 Jan 2024

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy specialist, has unveiled a breakthrough in cancer diagnostics, providing deeper, personalised and potentially actionable insights into the disease and its progression.

The company's latest innovation involves the expansion of its Parsortix system, which now includes DNA molecular analysis. This advancement allows for the detailed examination of both circulating tumour cells (CTCs) and fragments of DNA released by dying cells (ctDNA) from a single blood sample.

What the brokers say

07 Sep 2023

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a specialist in liquid biopsies for cancer detection, is showing early signs of progress despite industry headwinds.

The share price, up 12% in early afternoon trade, reflects the progress outlined in the company's interim results statement.

ANGLE's Parsortix technology, the first FDA-cleared product for harvesting circulating tumour cells (CTCs), is gradually cementing its position as the gold standard in a nascent but potentially lucrative market.

What management says

04 Jan 2024

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive and founder Andrew Newland visits the Proactive London studio to speak with Thomas Warner after the liquid biopsy company announced what it calls "groundbreaking" clinical results from its latest research.

ANGLE's research focused on addressing cancer's progression and the challenges of evolving treatments. Newland explains that traditional oncology relies on tissue biopsy for targeted therapy, but this method becomes ineffective as cancer changes. ANGLE's solution involves analysing both circulating tumour DNA (from dead cancer cells) and living cancer cells in blood, using their Parsortix system. This novel approach allows for repeated non-invasive biopsies, providing critical information on cancer evolution and treatment efficacy.

Their study involved 47 patients with four cancer types (breast, lung, ovarian, prostate) and identified actionable cancer mutations in living cells, not found in dead cells. These findings could lead to more effective, personalised treatments, as many of these variants are targetable with existing FDA-approved drugs.

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24